Sectors
ZBIO
Zenas BioPharma, Inc.
31.21
1 x 31.12
1 x 32.64
bid
ask
-
0.78
2.44%
09:37 AM
timesize
| Ytd | -14.05% | |
| 1y | 113.33% |
31.16
day range
31.80
13.50
52 week range
44.60
| Open | 31.43 | Prev Close | 31.99 | Low | 31.16 | High | 31.80 | Mkt Cap | 1.97B |
| Vol | 15.50K | Avg Vol | 791.13K | EPS | -5.03 | P/E | -6.20 | Forward P/E | -14.32 |
| Beta | -1.03 | Short Ratio | 11.05 | Inst. Own | 93.07% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 25.70 | 200-d Avg | 25.92 | 1yr Est | 43.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-11 | 2026-06 | -1.12 | N/A | N/A | N/A |
| 2026-05-13 | 2026-03 | -1.37 | -1.46 | -0.09 | -6.57% |
| 2026-03-16 | 2025-12 | -1 | -1.1 | -0.1 | -9.85% |
| 2025-11-12 | 2025-09 | -0.87 | -1.22 | -0.35 | -40.23% |
| 2025-08-12 | 2025-06 | -1.02 | -1.25 | -0.23 | -22.55% |
| 2025-05-15 | 2025-03 | -1.11 | -0.8 | 0.31 | 27.93% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-14 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
| 2026-03-17 | Citigroup | Upgrade | Buy | Buy |
| 2026-03-17 | Guggenheim | Upgrade | Buy | Buy |
| 2026-03-17 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
| 2026-03-17 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR, LLC | 9.08M | 294.53M | 14.39% |
| 2026-03-30 | SR One Capital Management, LP | 5.04M | 163.38M | 7.98% |
| 2026-03-30 | NEA Management Company, LLC | 4.02M | 130.47M | 6.37% |
| 2026-03-30 | Enavate Sciences Gp, LLC | 3.92M | 127.10M | 6.21% |
| 2026-03-30 | Federated Hermes, Inc. | 3.13M | 101.41M | 4.95% |
| 2026-06-29 | Blackrock Inc. | 2.69M | 87.11M | 4.25% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | SmallCap World Fund Inc | 2.43M | 78.93M | 3.86% |
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.34M | 43.60M | 2.13% |
| 2026-04-29 | Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 1.33M | 43.13M | 2.11% |
| 2026-04-29 | Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 1.25M | 40.61M | 1.98% |
| 2026-06-29 | Fidelity Select Portfolios-Select Health Care Portfolio | 1.08M | 35.02M | 1.71% |
| 2026-06-29 | Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.03M | 33.54M | 1.64% |
Dividend
| Dividend | Date |
|---|---|
| 0.002 | 2019-12-24 |
| 0.017 | 2019-09-25 |
| 0.015 | 2019-06-25 |
| 0.013 | 2019-03-20 |
| 0.005001 | 2018-12-26 |
Split
| Split | Date |
|---|---|
| 1 : 2 | 2018-05-24 |